Search - tctmd.com

Displaying 221 - 240 of 301

Sort: Relevancy | Date

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

News Daily News

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Michael O'Riordan

April 02, 2021

News Daily News

Did Regional Differences Muddy Results in COMMANDER-HF?

L.A. McKeown

February 04, 2021

News Opinion CV Team Dispatch

February 2021 News Roundup

L.A. McKeown

February 01, 2021

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Daily News

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

L.A. McKeown

January 11, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News AHA 2020

Simple Tech Empowers HF Patients, Boosting Health: EPIC-HF and MyROAD

L.A. McKeown

November 18, 2020

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Conference News AHA 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

Todd Neale

November 16, 2020

News Daily News

More Than Half of All HF Patients Take 10 or More Meds

L.A. McKeown

October 20, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

Shelley Wood

October 01, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

Todd Neale

August 30, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Daily News

HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds

Michael O'Riordan

August 13, 2020

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

Cannabis Has No CV Benefits and Substantial Risks, Says AHA Statement

Yael L. Maxwell

August 06, 2020

Advertisement

FDA Approves Dapagliflozin for CKD Patients

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Did Regional Differences Muddy Results in COMMANDER-HF?

February 2021 News Roundup

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

FDA Approves Vericiguat for High-risk Patients With HF

ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Simple Tech Empowers HF Patients, Boosting Health: EPIC-HF and MyROAD

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

More Than Half of All HF Patients Take 10 or More Meds

TCTMD’s Top 10 Most Popular Stories for September 2020

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Cannabis Has No CV Benefits and Substantial Risks, Says AHA Statement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content